CSIMarket



Kymera Therapeutics Inc.  (KYMR)
Other Ticker:  
 
 

KYMR's Capital Expenditures Growth by Quarter and Year

Kymera Therapeutics's Capital Expenditures results by quarter and year




KYMR Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.31 7.66 0.00
III Quarter September - 0.63 0.00 0.00
II Quarter June 0.74 0.16 0.00 0.00
I Quarter March 0.48 1.44 0.00 0.00
FY   1.22 2.54 7.66 -



KYMR Capital Expenditures second quarter 2022 Y/Y Growth Comment
Kymera Therapeutics Inc. achieved in the second quarter 2022, above Company average Capital Expenditures surge of 359.38% year on year, to $ 0.74 millions.

Looking into second quarter 2022 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Capital Expenditures growth. While Kymera Therapeutics Inc.' s Capital Expenditures doubling of 359.38% ranks overall at the positon no. 482 in the second quarter 2022.




KYMR Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -95.95 % - -
III Quarter September - - - -
II Quarter June 359.38 % - - -
I Quarter March -66.67 % - - -
FY   - -66.84 % - -

Financial Statements
Kymera Therapeutics's second quarter 2022 Capital Expenditures $ 0.74 millions KYMR's Income Statement
Kymera Therapeutics's second quarter 2021 Capital Expenditures $ 0.16 millions Quarterly KYMR's Income Statement
New: More KYMR's historic Capital Expenditures Growth >>


KYMR Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -50.79 % - -
III Quarter September - 293.75 % - -
II Quarter June 53.13 % -88.89 % - -
I Quarter March 54.84 % -81.2 % - -
FY (Year on Year)   - -66.84 % - -




Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #129
Overall #482

Capital Expenditures Y/Y Growth Statistics
High Average Low
220.63 % 31.91 % -91.47 %
(Sep 30 2021)   (Jun 30 2021)
Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #129
Overall #482
Capital Expenditures Y/Y Growth Statistics
High Average Low
220.63 % 31.91 % -91.47 %
(Sep 30 2021)   (Jun 30 2021)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Kymera Therapeutics's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
281.71 % 22.65 % -88.59 %
(Jun 30 2021)  


KYMR's II. Quarter Q/Q Capital Expenditures Comment
Kymera Therapeutics Inc. achieved in the II. Quarter 2022 above company average sequential Capital Expenditures jump of 53.13%, to $ 0.74 millions, from $0.48 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Kymera Therapeutics's Capital Expenditures growth quarter on quarter, overall rank is 906.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #234
Overall #906
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #234
Overall #906
Capital Expenditures Q/Q Growth Statistics
High Average Low
281.71 % 22.65 % -88.59 %
(Jun 30 2021)  


KYMR's II. Quarter Q/Q Capital Expenditures Comment
Kymera Therapeutics Inc. achieved in the II. Quarter 2022 above company average sequential Capital Expenditures jump of 53.13%, to $ 0.74 millions, from $0.48 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Kymera Therapeutics's Capital Expenditures growth quarter on quarter, overall rank is 906.


Kymera Therapeutics's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 2.15 $ 1.58 $ 2.53 $ 0.79 $ 9.26
Y / Y Capital Expenditures Growth (TTM) -76.79 % - - - -
Year on Year Capital Expenditures Growth Overall Ranking # 2692 # 0 # 0 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) 36.19 % -37.7 % 220.63 % -91.47 % -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 482 # 773 # 63 # 2331 # 0




Cumulative Capital Expenditures growth Comment
Kymera Therapeutics showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Mar 31 2022. If the fiscal year would end in Jun 30 2022, Kymera Therapeutics's annual Capital Expenditures drop would be -76.79% year on year to $2 millions.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 2692.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
220.63 %
31.91 %
-91.47 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 458
Overall # 2692

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-76.79 %
-76.79 %
-76.79 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 129
S&P 500 # 482
Cumulative Capital Expenditures growth Comment
Kymera Therapeutics showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Mar 31 2022. If the fiscal year would end in Jun 30 2022, Kymera Therapeutics's annual Capital Expenditures drop would be -76.79% year on year to $2 millions.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 2692.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
220.63 %
31.91 %
-91.47 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 458
Overall # 2692

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-76.79 %
-76.79 %
-76.79 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 129
S&P 500 # 482




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
KYMR's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for KYMR's Competitors
Capital Expenditures Growth for Kymera Therapeutics's Suppliers
Capital Expenditures Growth for KYMR's Customers

You may also want to know
KYMR's Annual Growth Rates KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio
KYMR's Roa KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2022
Alpine Immune Sciences Inc.616.67%$ 616.667 millions
Sonida Senior Living Inc.614.90%$ 614.896 millions
Surgepays Inc.591.75%$ 591.754 millions
Sensus Healthcare Inc.542.86%$ 542.857 millions
Vor Biopharma Inc.534.60%$ 534.603 millions
Biolargo Inc.527.27%$ 527.273 millions
Icosavax Inc.513.73%$ 513.732 millions
Acumen Pharmaceuticals Inc.500.00%$ 500.000 millions
Nanostring Technologies Inc.492.09%$ 492.086 millions
Twist Bioscience Corporation485.45%$ 485.451 millions
Armata Pharmaceuticals Inc.479.59%$ 479.592 millions
Applied Molecular Transport Inc.453.10%$ 453.103 millions
Dariohealth Corp.448.28%$ 448.276 millions
Voyager Therapeutics Inc.447.14%$ 447.137 millions
Viridian Therapeutics Inc.440.74%$ 440.741 millions
Maxcyte inc.435.39%$ 435.387 millions
Ocugen Inc.419.39%$ 419.392 millions
Caribou Biosciences Inc.417.79%$ 417.787 millions
Lifestance Health Group Inc.405.18%$ 405.176 millions
Adaptimmune Therapeutics Plc402.81%$ 402.806 millions
Pacific Health Care Organization Inc.401.50%$ 401.500 millions
Theralink Technologies Inc.392.64%$ 392.642 millions
Innovage Holding Corp381.78%$ 381.781 millions
Bionano Genomics Inc.376.92%$ 376.923 millions
Cytosorbents Corporation375.79%$ 375.791 millions
Pluri Inc.373.81%$ 373.810 millions
Celldex Therapeutics inc.370.63%$ 370.629 millions
Owens and Minor Inc.353.96%$ 353.956 millions
Immuneering Corp353.44%$ 353.438 millions
Kiromic Biopharma Inc.352.94%$ 352.940 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ORCL's Profile

Stock Price

ORCL's Financials

Business Description

Fundamentals

Charts & Quotes

ORCL's News

Suppliers

ORCL's Competitors

Customers & Markets

Economic Indicators

ORCL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071